Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Gross Margin: 2019-2023

Historic Gross Margin for ADC Therapeutics (ADCT) over the last 4 years, with Sep 2023 value amounting to 5.26%.

  • ADC Therapeutics' Gross Margin fell 9304.00% to 5.26% in Q3 2023 from the same period last year, while for Sep 2023 it was 45.54%, marking a year-over-year decrease of 5154.00%. This contributed to the annual value of 97.82% for FY2022, which is 193.00% up from last year.
  • As of Q3 2023, ADC Therapeutics' Gross Margin stood at 5.26%, which was down 78.97% from 25.03% recorded in Q2 2023.
  • ADC Therapeutics' 5-year Gross Margin high stood at 100.00% for Q3 2019, and its period low was 5.26% during Q3 2023.
  • Over the past 3 years, ADC Therapeutics' median Gross Margin value was 96.78% (recorded in 2021), while the average stood at 81.73%.
  • In the last 5 years, ADC Therapeutics' Gross Margin soared by 383bps in 2022 and then tumbled by 9,304bps in 2023.
  • Quarterly analysis of 5 years shows ADC Therapeutics' Gross Margin stood at 100.00% in 2019, then remained steady at 100.00% in 2020, then crashed by 382bps to 95.47% in 2021, then surged by 383bps to 99.30% in 2022, then tumbled by 9,304bps to 5.26% in 2023.
  • Its Gross Margin was 5.26% in Q3 2023, compared to 25.03% in Q2 2023 and 96.89% in Q1 2023.